Clinical use of aspirin in ischemic heart disease: past, present and future.
Aspirin is an antiplatelet drug, inhibiting the cyclooxygenase activity of platelet prostaglandin H synthase-1 and almost complete suppressing platelet capacity to generate the prothrombotic and proatherogenic thromboxane A2. Antiplatelet therapy with aspirin reduces the risk of serious vascular events by about a quarter in patients who are at high risk because they already have occlusive vascular disease. However, the inhibition of thromboxane-dependent platelet function by aspirin is effective for the prevention of thrombosis, but is also associated with excess bleeding, although the absolute increase in major gastrointestinal or other major extracranial bleeds is an order of magnitude smaller. For secondary prevention of vascular events, the benefits of aspirin therapy substantially exceed the risks. Therefore, aspirin is a cornerstone of antithrombotic therapy in acute coronary syndromes, in chronic ischemic heart disease and in percutaneous coronary intervention. On the other hand, the role of aspirin in primary prevention remains uncertain and it is still debated, because the absolute risk of vascular complications is the major determinant of the absolute benefit of antiplatelet prophylaxis and the reduction in vascular events needs to be weighed against any increase in major bleeds. Future data from ongoing studies will help us to identify people at high vascular risk who take advantage from aspirin therapy for primary prevention or will indicate if specific category of high risk patients, like patients with diabetes, could be better protected from an increase in the frequency of aspirin administration.
Institute of Cardiology, "G. d'Annunzio" University - Chieti, C/o Ospedale SS. Annunziata, Via dei Vestini, 66013 Chieti, Italy. rdecater@unich.it
Raffaele
R
De Caterina
Giulia
G
Renda
D000818:Animals; D001241:Aspirin / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D051545:Cyclooxygenase 1 / Q000097:blood; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy*; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use*; D011322:Primary Prevention / Q000266:history / Q000639:trends; D012307:Risk Factors; D055502:Secondary Prevention / Q000266:history / Q000639:trends; D013928:Thromboxane A2 / Q000097:blood; D016896:Treatment Outcome
D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013928:Thromboxane A2; D051545:Cyclooxygenase 1; D001241:Aspirin